UNSPSC 51285908: Pirtenidine

This classification denotes a topical anti-infective agent with the molecular formula C21H38N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier S6ON6743TM, chemically known as 1,4-dihydro-1-octyl-4-(octylimino)pyridine but more generally known as pirtenidine, which bears US NIH Compound Identifier 65879. European Medicines Agency schedules Pirtenidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09944MIG.

The term PIRTENIDINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 1, No. 4, 1987, List 27). PIRTENIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: N1(CCCCCCCC)CC/C(=N/CCCCCCCC)CC1.

UNSPSC 51285908 Pirtenidine (Commodity) shows minimal relevant recent state and local procurement activity; the code's nominal pharmaceutical scope does not align with the actual work appearing in recent solicitations under this classification. The four recent opportunities tagged to this code — naloxone and drug deactivation systems in Florida, a pharmacy direct-to-manufacturer initiative in Texas, fire department medical and first aid supplies in Tampa, and generic multi-source pharmaceuticals through a Minnesota cooperative purchasing alliance — span naloxone, emergency medical consumables, and broad-based pharmaceutical procurement, but contain no references to pirtenidine specifically. State and local issuers soliciting under this code include county health departments, state health and human services commissions, municipal fire departments, and cooperative purchasing alliances serving multi-state jurisdictions.

Recent opportunities reflect fragmented geographic activity across Florida, Texas, Minnesota, and Oregon, with no concentration in any single jurisdiction or region. Representative solicitations include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2026) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, the City of Tampa's sheltered-market IFB 26P00145 (posted March 25, 2026, due March 13, 2026) for 169 line items of medical and first aid supplies estimated at $700,000 with an SLBE bid discount, and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers. The mismatch between the code's stated pharmaceutical substance and the actual procurement activity suggests this code may be misapplied to these opportunities or the code itself may not be the appropriate classification for current state and local pharmaceutical procurement.